Rabourn Amy Zaremba
Known title: SVP of FinanceCIK: 0001832343
Associated companies
Transaction History
| IRD | ▼ Sell | Open Market | 1,641 | $9K | 4/23/2026 | View on chart |
| IRD | ▼ Sell | Open Market | 2,816 | $15K | 3/16/2026 | View on chart |
| IRD | ▲ Buy | Grant | 86,500 | $0 | 1/22/2026 | View on chart |
| IRD | ▼ Sell | Tax Withholding | 3,390 | $7K | 1/18/2026 | View on chart |
| IRD | ▼ Sell | Tax Withholding | 3,950 | $8K | 1/10/2026 | View on chart |
| IRD | ▲ Buy | Grant | 39,500 | $0 | 3/13/2025 | View on chart |
| IRD | ▼ Sell | Tax Withholding | 8,190 | $9K | 2/4/2025 | View on chart |
| IRD | ▲ Buy | Grant | 40,000 | $0 | 1/18/2024 | View on chart |
| IRD | ▼ Sell | Tax Withholding | 3,950 | $13K | 1/10/2024 | View on chart |
| IRD | ▲ Buy | Grant | 46,608 | $0 | 1/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Opus Genetics to Present at Euretina 2026
Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.
Opus Genetics to Present at Euretina 2026. Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.